Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Shapiro

Showing results (861-870 of 1,171) with videos related to

Pageof 118
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.
Cancer Research|August 19, 2015
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase InhibitionMargaret Soucheray, Marzia Capelletti, Inés Pulido, et al.
Iscience|September 8, 2022
Na/K-ATPase suppresses LPS-induced pro-inflammatory signaling through LynJue Zhang, Jackie Chang, Mirza Ahmar Beg, et al.
Critical Care Medicine|December 4, 2008
A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsisNathan I Shapiro, Stephen Trzeciak, Judd E Hollander, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.
Journal of the American Society of Nephrology : JASN|June 27, 2020
Central Role for Adipocyte Na,K-ATPase Oxidant Amplification Loop in the Pathogenesis of Experimental Uremic CardiomyopathyKomal Sodhi, Xiaoliang Wang, Muhammad Aslam Chaudhry, et al.
ESMO Open|April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphomaU M Lauer, A Awada, S Postel-Vinay, et al.
Cancer|October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumorsPhilippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Plos One|December 17, 2008
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET)Roland T Ullrich, Thomas Zander, Bernd Neumaier, et al.
Pageof 118

Showing results (861-870 of 1,171) with videos related to

Sort By:
Pageof 118
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.
Cancer Research|August 19, 2015
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase InhibitionMargaret Soucheray, Marzia Capelletti, Inés Pulido, et al.
Iscience|September 8, 2022
Na/K-ATPase suppresses LPS-induced pro-inflammatory signaling through LynJue Zhang, Jackie Chang, Mirza Ahmar Beg, et al.
Critical Care Medicine|December 4, 2008
A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsisNathan I Shapiro, Stephen Trzeciak, Judd E Hollander, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.
Journal of the American Society of Nephrology : JASN|June 27, 2020
Central Role for Adipocyte Na,K-ATPase Oxidant Amplification Loop in the Pathogenesis of Experimental Uremic CardiomyopathyKomal Sodhi, Xiaoliang Wang, Muhammad Aslam Chaudhry, et al.
ESMO Open|April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphomaU M Lauer, A Awada, S Postel-Vinay, et al.
Cancer|October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumorsPhilippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Plos One|December 17, 2008
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET)Roland T Ullrich, Thomas Zander, Bernd Neumaier, et al.
Pageof 118